Biossil
biossil.co
Actively hiring
Neurology & CNS Therapeutics
Oncology Therapeutics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Golden Ventures, Panache Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Golden Ventures 
Panache Ventures Similar startupsby what they do, their industry and backers
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Topas Therapeutics is…
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
ProteinQure is a Toronto biotechnology company founded in 2017 that designs peptide therapeutics computationally. Its platform combines…
BrainChild Bio is a kids-first, clinical-stage biotechnology company harnessing the power of CAR-T cell technology for tumors in the…
DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology…
Overview
Biossil is an AI native biopharma company based in Toronto. It is advancing late-stage programs in life-threatening indications with urgent unmet needs.
News
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Read more
Report
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Read more
Report
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
MIAMI, July 14, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artifi
Read more
Report
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Pro access
Upgrade to see all 19 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.